title: Development of Donor-Specific Anti-HLA Antibodies After Restarting Hemodialysis Due to Graft Failure.
abstract: BACKGROUND
  Incidents of renal replacement therapy (RRT) from renal transplants are on the rise. Some authors have associated the development of donor-specific anti-HLA antibodies (DSA) with the end of immunosuppression treatment (IS) and/or the performing of a transplantectomy. The objective of this study was to analyze the characteristics of transplant patients having high immunological risk who restarted RRT and the subsequent development of DSA.
  
  
  METHODS
  We selected incidents on RRT carried out between 1980 and 2012 in our center: 146 cases; they presented non-DSA cytotoxic antibodies prior to returning to RRT. Survival time for the graft was 77.2 months; the average follow-up period for DSA development was 131.9 months. DSA in 76 cases (52.1%). Of 146 grafts, 72 underwent transplantectomy and 41 presented DSA after returning to RRT. In 17 of these cases (41.5%), the development of DSA occurred prior to the transplantectomy. Fifty-one cases of DSA were registered at the date of completion of the IS treatment, and 40 appeared after discontinuation (median 36 weeks) and 11 with previous appearance. IS was completed, with a median of 13 weeks after the return to RRT.
  
  
  RESULTS
  No association was found between DSA development and order of graft, transplantectomy, or premature loss of the graft (≤15 months) after the return to RRT. There were significant differences between the number of HLA incompatibilities of the donor and the development of DSA.
  
  
  CONCLUSIONS
  The development of DSA in high-immunological risk patients after restarting RRT is not related to transplantectomy.
authors.affiliation: Fresenius Medical Care Andalucía, Córdoba, Spain. Electronic address: gamov84@gmail.com.
authors.forename: V
authors.initials: V
authors.lastname: García Montemayor
authors.affiliation: Córdoba Hospital Reina Sofía, Córdoba, Spain.
authors.forename: M L
authors.initials: ML
authors.lastname: Agüera
authors.affiliation: Hospital Doce De Octubre, Madrid, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Rabasco
authors.affiliation: Córdoba Hospital Reina Sofía, Córdoba, Spain.
authors.forename: M D
authors.initials: MD
authors.lastname: Navarro
authors.affiliation: Córdoba Hospital Reina Sofía, Córdoba, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Rodríguez Benot
authors.affiliation: Córdoba Hospital Reina Sofía, Córdoba, Spain.
authors.forename: P
authors.initials: P
authors.lastname: Aljama
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000917:Antibody Formation / Q000276:immunology*; D002648:Child; D005260:Female; D006084:Graft Rejection / Q000276:immunology*; D006085:Graft Survival; D006680:HLA Antigens; D006650:Histocompatibility Testing; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects*; D013997:Time Factors; D055815:Young Adult
chemical_list: D006680:HLA Antigens